Kiniksa Pharmaceuticals International, plc · Exercise / conversion · Class A Ordinary Share

What does this filing report?

An SEC Form 4 filing for Kiniksa Pharmaceuticals International, plc records an exercise / conversion involving Class A Ordinary Share on October 30, 2026. The reported quantity was 16,112. The filing date is November 3, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 29, 2026.

F2

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $91.36 to $92.35. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F3

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $92.36 to $93.31. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F4

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $93.37 to $94.36. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F5

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $94.375 to $95.215. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F6

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $95.485 to $96.405. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F7

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $96.54 to $97.48. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F8

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $97.60 to $98.30. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F9

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.64 to $91.63. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F10

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $91.64 to $92.525. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F11

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $92.732 to $93.725. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F12

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $93.94 to $94.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

F13

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.

F14

The option is fully vested and exercisable.

F15

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

F16

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024.

F17

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2025.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.